Meeting
2018 ASCO Annual Meeting
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Authors
Mark N. Stein
Columbia University Medical Center, New York, NY
Mark N. Stein , Jyoti Malhotra , Usha Malhotra , Ann W. Silk , Nancy Chan , Lorna Rodriguez-Rodriguez , Joseph Aisner , Robert Aiken , Jenna Newman , Evita Sadimin , Tracie Saunders , Melissa Frankel , Aparna Kareddula , Wafik S. El-Deiry , Rohinton Tarapore , Joshua E. Allen , Joseph R. Bertino , Steven K. Libutti , Janice M. Mehnert , Andrew Zloza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02250781; NCT02324621
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2595)
DOI
10.1200/JCO.2018.36.15_suppl.2595
Abstract #
2595
Poster Bd #
421
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
First Author: John Sarantopoulos
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2021 ASCO Annual Meeting
Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
First Author: Cai Zhou